Immediate Impact
1 standout
Citing Papers
Neoantigens: promising targets for cancer therapy
2023 Standout
Works of Amy King being referenced
A phase II trial of abemaciclib in patients with p16ink4a negative, relapsed mesothelioma.
2021
Author Peers
| Author | Last Decade | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|
| Amy King | 3 | 5 | 16 | 7 | 6 | 6 | 29 | |
| Rajshekhar Basak | 5 | 18 | 5 | 10 | 4 | 167 | ||
| E. S. Martsen | 3 | 14 | 9 | 13 | 7 | 178 | ||
| Felix Z. Meerson | 3 | 6 | 15 | 3 | 6 | 171 | ||
| Susan Nieschlag | 6 | 12 | 3 | 3 | 7 | 168 | ||
| John Randal Baker | 5 | 10 | 2 | 7 | 5 | 172 | ||
| Mayo Kodani | 8 | 9 | 4 | 7 | 9 | 168 | ||
| Vaitsa Tziaferi | 1 | 7 | 10 | 5 | 6 | 164 | ||
| J Pembroke | 1 | 9 | 5 | 2 | 8 | 164 | ||
| Jonathan Z. Luo | 9 | 14 | 2 | 7 | 7 | 171 | ||
| Eleanor Moncur | 6 | 5 | 14 | 2 | 10 | 169 |
All Works
Loading papers...